BIGBEAR
PHARMACEUTICAL
Belzutifan is a first-in-class oral small-molecule hypoxia-inducible factor-2α (HIF-2α) inhibitor.
AuthenticGuaranteeFast DeliveryPrivacy On May 14, 2025, Merck announced that the U.S. Food and Drug Administration (FDA) has approved Welireg (belzutifan) for the treatment of adult and ped···【More】
Update: 01 Apr,2026Source: BigbearViews: 113
On December 15, the U.S. Food and Drug Administration (FDA) approved Merck's oral treatment Welireg (belzutifan) for the treatment of adult patien···【More】
Update: 01 Apr,2026Source: BigbearViews: 138
On March 16, 2021, Merck announced that the U.S. FDA approved Welireg (belzutifan) for the treatment of adult patients with renal cell carcinoma (RCC)···【More】
Update: 01 Apr,2026Source: BigbearViews: 117
On May 14, 2025, Merck announced that the U.S. Food and Drug Administration (FDA) has approved Welireg (belzutifan) for the treatment of adult and ped···【More】
Update: 01 Apr,2026Source: BigbearViews: 113
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
